Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Accumulated Expenses (2018 - 2025)

Purple Biotech has reported Accumulated Expenses over the past 5 years, most recently at $3.6 million for Q4 2022.

  • Quarterly Accumulated Expenses rose 135.56% to $3.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2022, up 135.56% year-over-year, with the annual reading at $3.6 million for FY2022, 135.56% up from the prior year.
  • Accumulated Expenses was $3.6 million for Q4 2022 at Purple Biotech, up from $1.5 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $3.6 million in Q4 2022 and troughed at $255000.0 in Q4 2019.
  • The 5-year median for Accumulated Expenses is $880000.0 (2020), against an average of $1.4 million.
  • Year-over-year, Accumulated Expenses crashed 70.07% in 2019 and then surged 245.1% in 2020.
  • A 5-year view of Accumulated Expenses shows it stood at $852000.0 in 2018, then tumbled by 70.07% to $255000.0 in 2019, then surged by 245.1% to $880000.0 in 2020, then soared by 73.52% to $1.5 million in 2021, then soared by 135.56% to $3.6 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Accumulated Expenses are $3.6 million (Q4 2022), $1.5 million (Q4 2021), and $880000.0 (Q4 2020).